According to a new study published in the journal Radiology, the use of digital tomosynthesis breast, also known as three-dimensional mammography can significantly reduce the number of women who are doing a biopsy of breast due to benign tumors or false positive results.
Unlike the standard full-band or digital mammography, which fixes the two X-ray breast image, three-dimensional mammography captures multiple images at different angles, which are synthesized in 3D images using a computer.
"Thin slices of breast, obtained with the help of 3D mammography reduces aliasing tissue, which often leads to inaccurate results," - says a leading researcher Nisha Sharma, director of screening for breast cancer in Leeds educational NHS Trust hospital in England. - In the study, we wanted to determine the 3D effect on the incidence of biopsy mammography among women. "
The study involved 30,933 women who were screened PZPR or MRI breast screening in the framework of the National Program UK breast between 2015 and 2016 years. Within six weeks after the screening of breast cancer, women also do 3D mammography.
From the study group in 1470 women were offered an extra visualization (4,8-percentage Review) to assess deviations. In the last group of 827 women (mean age 56.7 years) took 571 biopsies, was 69 per cent resulting in a level of biopsy. A biopsy found 142 cases of cancer. In 429 of the biopsy suspicious neoplasm detected at screening mammography, there was no malignancy in benign biopsy 75%.
The researchers studied the image 3D mammography, to determine whether they are affected by the recommendation of the biopsy. Enabling 3D mammography screening would reduce the number of biopsies from 571 to 298, in view of the fact that 142 cases of cancer were also found.
«3D mammography improves the accuracy and confidence of the physician in the diagnosis and lead to a reduction in the number of biopsies, - says Dr. Sharma. - Our study confirms that the 3D visualization can help in the diagnosis of mammography violations and reduce the harm to women with fewer false-positive biopsies without compromising cancer detection. "